Slideshow: 2018 US Cannabis Business Year in Review

(Click on the orange arrows to advance the slideshow.)

2018 marked the historic legalization of recreational marijuana in Canada, the end of hemp prohibition in the United States and huge wins on Election Day for state-legal cannabis and medical marijuana initiatives across the U.S.

On the financial front, Big Booze, Tobacco and Pharma cracked their wallets open wide to invest in cannabis firms, and a slew of Canadian MJ companies debuted on the New York Stock Exchange and Nasdaq.

M&A headlines also dominated as consolidations and investments in cannabis firms rocketed.

Meanwhile, marijuana businesses watched carefully to see if another shoe would drop after the Cole Memo was rescinded by Attorney General Jeff Sessions earlier this year - but nothing happened. And by November, President Donald Trump had dumped Sessions.

Take a look back at these and other crucial marijuana business stories that broke this year in this slideshow.

Click here to view the International Year in Review.
Canada still at forefront of cannabis industry

Canada - already a world leader in the marijuana industry - became an even better place to do business after it became the first G-7 country to legalize recreational cannabis.

That will pave the way for other countries to follow, said former Prime Minister Brian Mulroney, and licensed producers spent the year opening markets in Africa, Asia, the Caribbean and Europe.
2018 Farm Bill legalizes hemp, and new law signals major changes for cannabis industry ahead

After months of delay, Congress overwhelmingly passed a Farm Bill in December that removed hemp - and hemp-derived CBD - from the Controlled Substances Act, and Trump signed it into law soon after.
Big Booze, Tobacco and Pharma make big marijuana bets

Major alcohol and tobacco firms upped their antes on cannabis in 2018, placing multibillion-dollar bids into expanding Canadian marijuana firms.

Among those wading into the cannabis industry: Constellation Brands, Molson Coors, AB InBev, Altria Group and a subsidiary of Swiss pharmaceutical giant Novartis AG.
Plant-touching companies list on Big Board and Nasdaq

Canada’s largest cannabis firms found their way onto the New York Stock Exchange and Nasdaq this year, positioning the companies to tap the globe’s largest pool of institutional investors.

Those greenlighted to list on the top U.S. exchanges include Cronos Group (Nasdaq), Canopy Growth (NYSE), Tilray (Nasdaq), Aurora Cannabis (NYSE) and Aphria (NYSE).
Cannabis consolidations and investments soar in 2018

Marijuana companies across the globe were on pace to raise a record $14 billion by the end of 2018 as more companies went public and scaled to meet growing demand.

Among the most notable U.S. deals sealed this year:

• New York-based Acreage Holdings raised $119 million to bankroll acquisitions and list its shares on the Canadian Securities Exchange. (Kevin Murphy, founder and CEO of Acreage Holdings, is shown above speaking at MJBizCon in November.)

• Chicago-based Cresco Labs had a $100 million funding round ahead of going public in Canada.

• Seattle-based Privateer Holdings completed a $100 million raise in January.

M&A activity also soared with major deals inked during the year, including Aurora’s acquisition of MedReleaf and CanniMed.

All told, 308 deals closed through mid-December - more than double the number last year.
Sessions rescinds Cole Memo; Trump rescinds Sessions
Sessions rescinds Cole Memo; Trump rescinds Sessions

In January, then-Attorney General Jeff Sessions rescinded the Cole Memo, a 2013 Department of Justice policy that essentially directed federal law enforcement to leave state-licensed cannabis businesses alone as long as they complied with certain guidelines.

But nothing happened after Sessions’ move, the marijuana industry continued to flourish, and by November he was out.

Donald Trump subsequently nominated William Barr, who served two years as attorney general under George H.W. Bush, to replace Sessions. Still to be confirmed, Barr’s current stance on marijuana policy is unclear.
Legal marijuana took a $2 billion+ step forward in 2018 through state elections

Voters approved recreational cannabis in Michigan and medical marijuana in Missouri, Oklahoma and Utah.

The four markets are expected to generate up to $2.25 billion in combined annual sales within several years of launching their programs, according to the Marijuana Business Factbook 2018.
DEA takes some CBD medicines off Schedule 1

The U.S. Food and Drug Administration in June approved a naturally derived CBD drug, Epidiolex.

The landmark decision triggered a new classification for the cannabinoid from the Drug Enforcement Administration. The DEA announced that drugs including “finished dosage formulations” of CBD with THC below 0.1% will be considered Schedule 5 drugs, provided the medications have been approved by the FDA.
MJ entrepreneurs across the U.S. work in an increasingly mainstream industry

The four major new U.S. state cannabis markets to roll out in 2018 included adult-use sales in California and Massachusetts along with medical cannabis in Pennsylvania and Oklahoma.

Those launches brought the functioning cannabis industry in the United States even further into the mainstream, given that all four formally legalized recreational or medical in just the past two years.
Marijuana wholesale prices crashing

As it turns out, there can be too much of a good thing.

Beginning with the 2017 fall outdoor harvest, wholesale prices of flower in several mature U.S. cannabis markets have trended steadily downward, caused largely by an overabundance of product.

In particular, cultivators in Colorado, Oregon and Washington state watched as wholesale prices of pounds of flower fell by double-digit percentages.

According to Oregon growers, indoor-grown wholesale cannabis prices in the state dropped 30%-50% from last year, and Colorado and Washington’s declines weren’t far behind.
2 comments on “Slideshow: 2018 US Cannabis Business Year in Review
  1. Adam on

    Prices crashing isn’t a bad thing, it’s a great thing! 1 dose of Tylenol costs a few pennies, yet 1 dose of Cannabis ~$1. That’s crazy. Black market prices were terrible for accessibility and we could not be looking at those prices as something we reminisce. As policy makers and entrepreneurs, we should create organizations that serve humanity, not strive for profits for businesses… Duh.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *